These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 10223941)
1. Pharmacokinetics of rifapentine in subjects seropositive for the human immunodeficiency virus: a phase I study. Keung AC; Owens RC; Eller MG; Weir SJ; Nicolau DP; Nightingale CH Antimicrob Agents Chemother; 1999 May; 43(5):1230-3. PubMed ID: 10223941 [TBL] [Abstract][Full Text] [Related]
2. Novel dosing strategies increase exposures of the potent antituberculosis drug rifapentine but are poorly tolerated in healthy volunteers. Dooley KE; Savic RM; Park JG; Cramer Y; Hafner R; Hogg E; Janik J; Marzinke MA; Patterson K; Benson CA; Hovind L; Dorman SE; Haas DW; Antimicrob Agents Chemother; 2015; 59(6):3399-405. PubMed ID: 25824215 [TBL] [Abstract][Full Text] [Related]
3. Single-dose pharmacokinetics of rifapentine in elderly men. Keung AC; Eller MG; Weir SJ Pharm Res; 1998 Aug; 15(8):1286-91. PubMed ID: 9706063 [TBL] [Abstract][Full Text] [Related]
4. Single and multiple dose pharmacokinetics of rifapentine in man: part II. Keung A; Eller MG; McKenzie KA; Weir SJ Int J Tuberc Lung Dis; 1999 May; 3(5):437-44. PubMed ID: 10331734 [TBL] [Abstract][Full Text] [Related]
5. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium. Vernon A; Burman W; Benator D; Khan A; Bozeman L Lancet; 1999 May; 353(9167):1843-7. PubMed ID: 10359410 [TBL] [Abstract][Full Text] [Related]
6. Enzyme induction observed in healthy volunteers after repeated administration of rifapentine and its lack of effect on steady-state rifapentine pharmacokinetics: part I. Keung A; Reith K; Eller MG; McKenzie KA; Cheng L; Weir SJ Int J Tuberc Lung Dis; 1999 May; 3(5):426-36. PubMed ID: 10331733 [TBL] [Abstract][Full Text] [Related]
7. Effects of four different meal types on the population pharmacokinetics of single-dose rifapentine in healthy male volunteers. Zvada SP; Van Der Walt JS; Smith PJ; Fourie PB; Roscigno G; Mitchison D; Simonsson US; McIlleron HM Antimicrob Agents Chemother; 2010 Aug; 54(8):3390-4. PubMed ID: 20516273 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic interaction of rifapentine and raltegravir in healthy volunteers. Weiner M; Egelund EF; Engle M; Kiser M; Prihoda TJ; Gelfond JA; Mac Kenzie W; Peloquin CA J Antimicrob Chemother; 2014 Apr; 69(4):1079-85. PubMed ID: 24343893 [TBL] [Abstract][Full Text] [Related]
9. Once-weekly rifapentine and isoniazid for tuberculosis prevention in patients with HIV taking dolutegravir-based antiretroviral therapy: a phase 1/2 trial. Dooley KE; Savic R; Gupte A; Marzinke MA; Zhang N; Edward VA; Wolf L; Sebe M; Likoti M; Fyvie MJ; Shibambo I; Beattie T; Chaisson RE; Churchyard GJ; Lancet HIV; 2020 Jun; 7(6):e401-e409. PubMed ID: 32240629 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of rifapentine in patients with varying degrees of hepatic dysfunction. Keung AC; Eller MG; Weir SJ J Clin Pharmacol; 1998 Jun; 38(6):517-24. PubMed ID: 9650541 [TBL] [Abstract][Full Text] [Related]